ZEVRA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.16 USD | -0.29% |
|
+12.17% | -21.22% |
| May. 08 | Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M | MT |
| Apr. 15 | Zevra Therapeutics Metabolic Disorder Treatment Shows 'Meaningful Slowing of Disease Progression' | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 29.37M | Sales 2025 * | 92.78M | Capitalization | 217M |
|---|---|---|---|---|---|
| Net income 2024 * | -69M | Net income 2025 * | -16M | EV / Sales 2024 * | 7.95 x |
| Net Debt 2024 * | 16.8M | Net Debt 2025 * | 14.8M | EV / Sales 2025 * | 2.49 x |
| P/E ratio 2024 * |
-3.25
x | P/E ratio 2025 * |
-9.99
x | Employees | 67 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zevra Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -0.29% | ||
| 1 week | +12.66% | ||
| Current month | +12.66% | ||
| 1 month | +7.05% | ||
| 3 months | -11.19% | ||
| 6 months | +17.27% | ||
| Current year | -21.22% |
1 week
4.61
5.30
1 month
4.395.30
Current year
4.397.28
1 year
3.897.28
3 years
3.8915.70
5 years
1.9432.00
10 years
1.94418.40
| Managers | Title | Age | Since |
|---|---|---|---|
Christal Mickle
FOU | Founder | 45 | 06-10-29 |
Neil McFarlane
CEO | Chief Executive Officer | 51 | 23-10-09 |
R. Clifton
DFI | Director of Finance/CFO | 51 | 15-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wendy Dixon
BRD | Director/Board Member | 68 | 23-04-24 |
Tamara Favorito
CHM | Chairman | 65 | 21-08-17 |
| Director/Board Member | 56 | 23-04-24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.44% | 4 M€ | -5.15% | - | |
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 5.16 | -0.29% | 229,449 |
| 24-05-07 | 5.175 | +0.39% | 305,903 |
| 24-05-06 | 5.155 | +7.17% | 310,448 |
| 24-05-03 | 4.81 | +1.26% | 169,547 |
| 24-05-02 | 4.75 | +3.26% | 135,611 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotes
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.16
USD
Average target price
19
USD
Spread / Average Target
+268.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.22% | 217M | |
| +6.97% | 71.94B | |
| -10.86% | 5.13B | |
| +46.43% | 4.66B | |
| +5.38% | 3.97B | |
| -16.20% | 2.55B | |
| +21.10% | 2.41B | |
| -26.20% | 2.36B | |
| +19.92% | 2.21B | |
| +8.15% | 1.71B |
- Stock Market
- Equities
- ZVRA Stock